Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,333 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $55.69, for a total transaction of $4,640,814.77. Following the transaction, the chief executive officer now owns 272,768 shares of the company’s stock, valued at approximately $15,190,449.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Nektar Therapeutics (NASDAQ NKTR) traded up $1.85 during trading hours on Friday, hitting $56.90. 3,711,627 shares of the stock were exchanged, compared to its average volume of 1,710,505. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $57.83. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The company had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. During the same quarter in the previous year, the company posted ($0.32) earnings per share. Nektar Therapeutics’s quarterly revenue was up 321.2% compared to the same quarter last year. sell-side analysts anticipate that Nektar Therapeutics will post -0.75 EPS for the current year.
A number of brokerages have commented on NKTR. Canaccord Genuity raised their price target on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, November 13th. Canaccord Genuity Group raised their price target on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Roth Capital set a $45.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Mizuho raised their price target on shares of Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Finally, J P Morgan Chase & Co restated a “buy” rating and set a $44.00 price target on shares of Nektar Therapeutics in a research note on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $35.58.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.